Effective leadership in an innovation-driven company isn't about being 'tough' but 'demanding' of high standards. The Novonesis CEO couples this with an explicit acceptance of failure as an inherent part of R&D, stressing the need to 'fail fast' and learn from it.

Not all failures are equal. Innovation teams must adopt a framework for evaluating failures based on their cost-to-learning ratio. A 'brilliant failure' maximizes learning while minimizing cost, making it a productive part of R&D. An 'epic failure' spends heavily but yields little insight, representing a true loss.

Dealing with regulatory bodies can be terrifying, especially for a startup facing a recall. The key is to present objective facts, demonstrate a rigorous process, and make decisions that protect the product and patient. This builds trust and ensures long-term viability.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

Instead of just declaring a "fail fast" policy, BetterRx CEO Ben Clark integrated it into the company's core value of "there's always a better way." This reframed experimentation and small failures as an expected part of the continuous improvement process, encouraging rapid testing and learning across the organization.

A major product recall forced a CMO to conduct a forensic analysis of 96 issues across the entire supply chain, far outside his marketing role. This unwanted, deep operational knowledge became the foundation for the company's subsequent record-breaking growth.

During difficult periods, such as a failed clinical trial, the worst action a company can take is to cease communication. Continuously talking to investors, even when the news is bad, maintains trust and demonstrates resilience. Transparency in tough times is crucial for long-term investor relationships.

Instead of stigmatizing failure, LEGO embeds a formal "After Action Review" (AAR) process into its culture, with reviews happening daily at some level. This structured debrief forces teams to analyze why a project failed and apply those specific learnings across the organization to prevent repeat mistakes.

In high-stakes fields like medtech, the "fail fast" startup mantra is irresponsible. The goal should be to "learn fast" instead—maximizing learning cycles internally through research and simulation to de-risk products before they have real-world consequences for patient safety.